Food and Drug Administration (FDA)
NEWS
Robert Gadimian, a former executive with Puma Biotechnology, was sentenced to more than two years in prison for insider trading.
Shares of Bedford, Mass.-based Anika Therapeutics have plunged more than 20 percent in premarket trading.
Array is anxiously awaiting the FDA to approve its combination treatment for BRAF-mutant metastatic melanoma. If approved, Chief Executive Officer Ron Squarer believes it will not only be an important milestone for the company, but also for the patients.
Boston-based Emulate closed on a Series C round worth $36 million.
Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.
The U.S. Food and Drug Administration (FDA) placed a clinical hold on Boston-based Ziopharm Oncology’s Phase I trial of its Sleeping Beauty CAR-T therapy.
Shares of Solid Biosciences have jumped 11 percent in premarket trading after the company announced the U.S. Food and Drug Administration has lifted a clinical hold on the company’s Phase I/II clinical trial gene therapy treatment for Duchenne muscular dystrophy (DMD).
Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.
Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.
JOBS
IN THE PRESS